Zhejiang NHU Company Ltd. (SHE:002001)
China · Delayed Price · Currency is CNY 27.02
-0.12 (-0.44%)
Aug 31, 2026, 3:04 PM CST
Zhejiang NHU Company Revenue
Zhejiang NHU Company had revenue of 6.83B CNY in the quarter ending June 30, 2026, with 20.73% growth. This brings the company's revenue in the last twelve months to 24.28B, up 6.19% year-over-year. In the year 2025, Zhejiang NHU Company had annual revenue of 22.25B with 2.97% growth.
Revenue (ttm)
24.28B
Revenue Growth
+6.19%
P/S Ratio
3.43
Revenue / Employee
2.11M
Employees
11,508
Market Cap
83.28B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 22.25B | 641.77M | 2.97% |
| Dec 31, 2024 | 21.61B | 6.49B | 42.95% |
| Dec 31, 2023 | 15.12B | -817.45M | -5.13% |
| Jan 1, 2023 | 15.93B | 1.02B | 6.82% |
| Jan 1, 2022 | 14.92B | 4.60B | 44.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 44.00B |
| Shanghai Fosun Pharmaceutical (Group) | 42.59B |
| Yunnan Baiyao Group Co.,Ltd | 41.95B |
| China Resources Sanjiu Medical & Pharmaceutical | 31.81B |
| Humanwell Healthcare (Group) | 23.96B |
| Beijing Tongrentang | 16.64B |
| Changchun High-Tech Industry (Group) | 11.02B |
| Dong-E-E-Jiao | 6.80B |
Zhejiang NHU Company News
- 11 days ago - Zhejiang NHU Company Quarterly report: Q2 2026 - Filings
- 4 months ago - Zhejiang NHU Company Quarterly report: Q1 2026 - Filings
- 4 months ago - Zhejiang NHU Company Annual report: Q4 2025 - Filings
- 10 months ago - Zhejiang NHU Company Quarterly report: Q3 2025 - Filings